- MS Pharma Group has signed an exclusive partnership with Hetero Group to localize five established biosimilars in Algeria.
- The collaboration will be implemented through El Kendi and Hetero Biopharma, with an estimated market value of $45 million in 2024.
MS Pharma Group has entered into a strategic partnership with Hetero Group to localize five established biosimilars across oncology, immunology, and hematology in Algeria. The agreement aims to expand access to biologic medicines through a localization and technology transfer approach.
The exclusive collaboration will be implemented through El Kendi, MS Pharma Group’s affiliate in Algeria, and Hetero Biopharma. It represents Hetero Group’s first local partnership in the country and is positioned to support the development of Algeria’s biopharmaceutical ecosystem.
According to the companies, the combined biosimilars portfolio has an estimated total market value of USD 45 million in Algeria in 2024. The partnership is structured around localization and technology transfer to support sustainable supply and local capability building.
“We are pleased to collaborate with a global partner like Hetero, with whom we share a long-term commitment to knowledge transfer and improving healthcare outcomes for patients in the region.”
Kalle Känd, CEO of MS Pharma Group
